Health literacy is experiencing new challenges, and Medical Affairs is uniquely positioned to lead and partner with others in this space to ensure coordination, credibility and impact.
MEDICAL AFFAIRS: The Roles, Value and Practice of Medical Affairs in the Biopharmaceutical and Medical Technology Industries (Taylor & Francis, 2024)
MAPS speaks with Liz de Somer, CEO of Medicines Australia and Sharon Winton, CEO of Lymphoma Australia to explore patient engagement from the perspectives of industry and patient associations.
In this on-demand webinar, our experts provide guidance and potential solutions on addressing major barriers for patient centricity initiatives identified through their survey.
This paper provides a vision describing how Gen AI technologies will reshape the possibilities and practice of Medical Affairs related to the four functional pillars of Strategy & Leadership, Evidence & Insights Generation, Evidence & Insights Communication, and Engagement & Partnerships.
The Medical community knows it needs to improve equity in clinical trials, but what really helps when it comes to changing patient and provider perceptions? PlatformQ Health is pleased to share insights into strategies for helping patients become more receptive to trial participation and supporting providers in fostering inclusion.
In this webinar we will explore practical approaches to engaging patients in early development, introducing key resources and discussing best practices. These discussions will be tailored to meet the needs of all Medical Affairs colleagues, regardless of experience.
By using the framework of Explore, Educate, Embrace we can shape our approach to Health Equity by incorporating it into our daily work.
Streamlining the diagnostic odyssey requires educating medical professionals to recognize “rare encounters” and engage these patients with precision and compassion.
MAPS speaks with Annemarie Clegg, CMO, OPEN Health, about the evolving role of Medical Affairs in providing context for payers, regulators and policy makers whose decisions can dramatically affect which patients can access industry innovations.